# RapidAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rapidai

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.rapidai.com
- Total disclosed funding: $75M
- Latest round: Series C (Jul 20, 2023)
- Investors on record: 1

## About

Founded in 2012 and based in Colorado, iSchemaView, Inc. is a clinical AI company focused on enhancing decision support tools for neurovascular care, improving outcomes through advanced data analytics and real-time insights.iSchemaView, Inc. specializes in developing AI-driven solutions for clinical decision-making, particularly in neurovascular conditions. The company was founded in Menlo Park, US, and has undergone significant growth, with its latest funding round, a Series C, completed in July 2023, raising USD 75.00 mn from Vista Equity Partners. The company has not reported any pivots or changes in business strategy since its inception. The founding history includes the leadership of CEO Don Listwin alongside Karim Karti, contributing to a foundational ethos of innovation in healthcare.RapidAI is a clinical AI platform specializing in decision support tools tailored for various disease states, particularly in neurovascular care. Its core offerings include rapid assessment solutions for ischemic strokes, hemorrhagic events, and aneurysms, which enhance clinical decision-making through real-time data analysis and AI-driven insights. The platform facilitates imaging prioritization and alerts for urgent cases, enabling clinicians to identify suspected anomalies and automate key metrics such as blood flow and anomaly growth. RapidAI's products are designed to integrate seamlessly into existing healthcare systems, ensuring interoperability across the healthcare ecosystem. The company serves a broad client base that includes hospitals and healthcare providers primarily in North America, Europe, and Asia, aimed at enhancing patient care and operational efficiency.RapidAI's revenue model primarily revolves around subscription-based partnerships with healthcare institutions that utilize its AI-driven clinical solutions. Clients engage with the platform on a recurring basis, which allows for continuous access to advanced analytics, clinical decision support, and ongoing updates. The company's flagship offerings include proprietary tools for rapid detection and assessment of stroke and aneurysm-related conditions, which are pivotal in emergency medical settings. Pricing structures are tailored to the specific needs of healthcare providers, based on their scale and operational requirements, typically involving agreements that cover software licensing, implementation support, and training for clinical staff.In July 2023, RapidAI raised USD 75.00 mn in Series C funding, led by Vista Equity Partners, which will be utilized to develop its platform to support more disease states and expand its market reach. The company plans to introduce new products designed to enhance its offering in neurovascular care and is targeting expansion into new geographic regions, including Europe and Asia, by the end of 2024. This strategic growth plan is aimed at increasing the accessibility and applicability of its AI-driven solutions in diverse healthcare environments.

## Funding rounds

- Series C, Jul 20, 2023, $75M — Vista Equity Partners

## Investors

- Vista Equity Partners (https://capitalatlas.ai/funds/vista-equity-partners) — Series C